For example, treatment with GLP-1 RAs and/or SGLT2 inhibitors is recommended to those with DM2 and established ASCVD or multiple risk factors, independent of their level of glycemic control [1,52,53,54]. This evidence concerns the gene SLC5A2 and atherosclerosis.